CCDC126 Activators
CCDC126 Activators are a diverse set of chemical compounds that can influence the activity of CCDC126 through various cellular signaling pathways. Forskolin, by increasing cAMP levels, may enhance CCDC126 activity if CCDC126 operates in cAMP-dependent signaling. Similarly, PMA, as a PKC activator, could augment CCDC126 activity by activating PKC-dependent pathways. In contrast, Ionomycin and A23187 act as calcium ionophores, which could activate CCDC126 through calcium-dependent signaling pathways. Sphingosine-1-phosphate, a bioactive lipid, engages G protein-coupled receptors, potentially modulating CCDC126 activity through these pathways. EGCG, through its inhibition of kinases, and Genistein, as a tyrosine kinase inhibitor, might also enhance CCDC126 activity by reducing inhibitory kinase signaling that would otherwise dampen its function.
Furthermore, small molecule inhibitors such as the PI3K inhibitors LY294002 and Wortmannin, the MEK inhibitor U0126, and the p38 MAPK inhibitor SB203580, could indirectly enhance CCDC126 activity by altering downstream signaling pathways. If CCDC126 is negatively regulated by the PI3K/AKT pathway, PI3K inhibition could relieve this negative regulation, thus enhancing CCDC126 activity. Inhibiting MEK and p38 MAPK might also shift signaling dynamics that favor CCDC126activation if it is part of pathways that are suppressed by ERK or p38 MAPK activity. Lastly, Staurosporine, a broad-spectrum protein kinase inhibitor, might lead to a selective increase in CCDC126 activity by inhibiting kinases that exert negative control over CCDC126-associated pathways. Collectively, these activators, through their targeted modulation of specific signaling pathways, have the potential to enhance the functional activity of CCDC126 without directly increasing its expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that increases intracellular cAMP levels, which could lead to the phosphorylation of downstream targets by PKA, potentially enhancing the functional activity of CCDC126 if CCDC126 activity is modulated by cAMP-dependent processes. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PKC activator that mimics diacylglycerol (DAG), potentially leading to the activation of PKC-dependent pathways. If CCDC126 is a substrate or is regulated by PKC, its activity could be enhanced. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Selective calcium ionophore that increases intracellular calcium levels, potentially inducing calcium-dependent pathways that may enhance the functional activity of CCDC126 if it is involved in or regulated by such pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A potent antioxidant that also acts as a kinase inhibitor, potentially altering signaling pathways that could enhance the functional activity of CCDC126 if it is downstream of kinase-regulated processes. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
A bioactive lipid that acts through G protein-coupled receptors to activate multiple signaling pathways, which could lead to enhanced CCDC126 activity if CCDC126 functions are modulated by S1P signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could lead to altered AKT signaling, potentially enhancing CCDC126 activity if it is negatively regulated by the PI3K/AKT pathway and thus indirectly activating CCDC126 by inhibition of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that could lead to reduced ERK signaling, potentially enhancing the functional activity of CCDC126 if CCDC126 is involved in pathways that are negatively impacted by ERK activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could shift the signaling balance to enhance CCDC126 activity if CCDC126 functions in a pathway that is negatively regulated by p38 MAPK. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A calcium ionophore that increases intracellular calcium levels, potentially activating CCDC126 if it is involved in calcium-dependent signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A tyrosine kinase inhibitor that could enhance CCDC126 functional activity by reducing competitive tyrosine kinase signaling, if CCDC126 is regulated by or associated with tyrosine kinase pathways. | ||||||